New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology

New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology

Abstract Until recently the application of artificial intelligence (AI) in precision oncology was confined to activities in drug development and had limited impact on the personalisation of therapy. Now, a number of approaches have been proposed for the personalisation of drug and cell therapies wit...

Full description

Bibliographic Details
Main Authors: Bouchra Derraz, Gabriele Breda, Christoph Kaempf, Franziska Baenke, Fabienne Cotte, Kristin Reiche, Ulrike Köhl, Jakob Nikolas Kather, Deborah Eskenazy, Stephen Gilbert
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00517-w

Internet

https://doi.org/10.1038/s41698-024-00517-w

Similar Items